Evidence map›Paper›PMID 25550354›Full record

ArticleJournal of biomolecular screening2015

The combined use of alphavirus replicons and pseudoinfectious particles for the discovery of antivirals derived from natural products.

Phillip C Delekta, Avi Raveh, Martha J Larsen, Pamela J Schultz, Giselle Tamayo-Castillo, David H Sherman, David J Miller

Open access · hybridAbstract read
In one paragraph

Article in Journal of biomolecular screening, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Antiviral potential of natural products from marine microbes.European journal of medicinal chemistry · 2020
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Phillip C DelektaDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Avi RavehLife Sciences Institute, University of Michigan, Ann Arbor, MI, USA.
Martha J LarsenCenter for Chemical Genomics, University of Michigan, Ann Arbor, MI, USA.
Pamela J SchultzLife Sciences Institute, University of Michigan, Ann Arbor, MI, USA.
Giselle Tamayo-CastilloNational Institute of Biodiversity (INBio), Universidad de Costa Rica, San José, Costa Rica.
David H ShermanDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA Department of Chemistry and Medicinal Chemistry, University of Michigan, Ann Arbor, MI, USA Life Sciences Institute, University of Michigan, Ann Arbor, MI, USA.
David J MillerDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA milldavi@umich.edu.
University of Michigan–Ann Arbor · USUniversidad de Costa Rica · CR

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
Vaccines and Therapies Against BotulismU54AI057153 · NIAID · UNIVERSITY OF CHICAGO · PI NIZET, VICTOR · 2003 to 2013
$87.6M
of Natural Product based Drugs and Bioenergetic Materials from Costa Rican BiotaU01TW007404 · FIC · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHERMAN, DAVID H · 2005 to 2013
$7.6M
Marine Microbial Products as Novel Agents Against Neurotropic ArbovirusesR21AI093642 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MILLER, DAVID J · 2011 to 2012
$428k
FIC NIH HHS U01 TW007404NCI NIH HHS P30 CA046592NIAID NIH HHS R21 AI093642NIAID NIH HHS U54 AI057153
6 · The paper itself

Abstract

Alphaviruses are a prominent class of reemergent pathogens due to their globally expanding ranges, potential for lethality, and possible use as bioweapons. The absence of effective treatments for alphaviruses highlights the need for innovative strategies to identify antiviral agents. Primary screens that use noninfectious self-replicating RNAs, termed replicons, have been used to identify potential antiviral compounds for alphaviruses. Only inhibitors of viral genome replication, however, will be identified using replicons, which excludes many other druggable steps in the viral life cycle. To address this limitation, we developed a western equine encephalitis virus pseudoinfectious particle system that reproduces several crucial viral life cycle steps in addition to genome replication. We used this system to screen a library containing ~26,000 extracts derived from marine microbes, and we identified multiple bacterial strains that produce compounds with potential antiviral activity. We subsequently used pseudoinfectious particle and replicon assays in parallel to counterscreen candidate extracts, and followed antiviral activity during biochemical fractionation and purification to differentiate between inhibitors of viral entry and genome replication. This novel process led to the isolation of a known alphavirus entry inhibitor, bafilomycin, thereby validating the approach for the screening and identification of potential antiviral compounds.

Indexed as

AlphavirusAnimalsAntiviral AgentsBiological ProductsCell LineDose-Response Relationship, DrugDrug DiscoveryHigh-Throughput Screening AssaysHumansInhibitory Concentration 50Microbial Sensitivity TestsReproducibility of ResultsSmall Molecule LibrariesVirus ReplicationAntiviral AgentsBiological ProductsSmall Molecule Librariesalphavirusantiviral screeningbiosafety

Identifiers

PMID25550354
PMCPMC4439314
OpenAlexW2169192118

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.